Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that final data from …
As Intercept Pharmaceuticals Inc (NASDAQ:ICPT) approaches a crucial date for FDA approval of a liver disease treatment and Rexahn Pharmaceuticals, Inc (NYSE:RNN) announces its YE15 earnings …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the fourth …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase approximately 15.
Healthcare analysts weighed in today on small biopharmaceutical firms Relypsa Inc (NASDAQ:RLYP) and Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), following meeting with management and Phase II clinical trial …
Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it has identified …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that the Company presented …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it presented new …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced additional interim clinical data from …
